|

Letrozole tablets Clinical Trials

5 actively recruiting trials

No change since May 2026

Pipeline

Phase 3: 3Phase 1/2: 2

Top Sponsors

  • Shandong Suncadia Medicine Co., Ltd.3
  • Jiangsu HengRui Medicine Co., Ltd.1
  • Ente Ospedaliero Ospedali Galliera1

Indications

  • Cancer5
  • Breast Cancer4
  • Advanced Unresectable or Metastatic Breast Cancer of Adults1
  • Low Grade Serous Adenocarcinoma of Ovary1
  • Carcinoma, Ovarian Epithelial1

Other5 trials

A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
Phase 1/2
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Phase 3
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
Phase 3
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
Phase 1/2
Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.